Российский кардиологический журнал (Jun 2024)
Effectiveness of neoton in patients with heart failure receiving sacubitril/valsartan. Sub-analysis of the BYHEART study
Abstract
Aim. To study the effectiveness of exogenous phosphocreatine (EP) therapy in patients with heart failure (HF) with reduced and mildly reduced ejection fraction (EF) receiving sacubitril/valsartan.Material and methods. The nationwide prospective observational study BYHEART included a total of 842 patients who underwent intravenous EP therapy. To achieve this goal, a group of patients was identified that received sacubitril/valsartan (n=139). Before and after the EP course, the following methods were used: the Minnesota Living with Heart Failure Questionnaire (MLHFQ), Rating Scale of Clinical State, transthoracic echocardiography assessing left ventricular EF (LVEF), 6-minute walk test (6MWT), assessment of NT-proBNP level.Results. Of the 139 patients included in the study, 69,06% (n=96) were male. The mean age was 62,89±12,2 years. Of the entire cohort of patients with HF, 50 patients had class II (35,97%), 80 — class III (57,56%), 9 — class IV (6,47%). EP therapy led to a significant improvement in the quality of life (from 67±17 to 49±16, p<0,01, delta -6,7), a decrease in the Rating Scale of Clinical State score (from 7,7±2,8 to 5,6±2,1, p<0,01, delta -2,2), an increase in 6MWT distance (from 261±85 m to 310±74 m, p<0,01, delta 49 m), LVEF (from 38,5±7,01% to 40,25±6,58%, p<0,01, delta 1,75%), decreased NT-proBNP concentration (from 1000 [602; 1869] pg/ml to 832 [469; 1614] pg/ml, p<0,01).Conclusion. The results obtained demonstrate that adjuvant intravenous mitochondrial EP therapy in patients with HF receiving sacubitril/valsartan improves quality of life, decrease the Rating Scale of Clinical State score and NT-proBNP concentration, as well as increase 6MWT distance and LVEF.
Keywords
